Salt and crystal forms of sulfonylurea ring-substituted compounds
Crystalline form A of sulfonylurea ring-substituted monocyclic β-lactam compounds addresses drug resistance by providing stability to serine and metallo-β-lactamases, offering broad antibacterial activity and effective treatment of drug-resistant infections.
Patent Information
- Application Number
- JP2023511593
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-12
- Filing Date
- 2022-10-20
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2042-10-20
AI Technical Summary
The emergence of drug-resistant bacteria, particularly those expressing metallo-β-lactamases (MBLs), has rendered traditional antibiotics like penicillins, cephalosporins, and carbapenems ineffective, necessitating the development of new monocyclic β-lactam antibiotics that are stable against these enzymes.
The development of crystalline form A of sulfonylurea ring-substituted monocyclic β-lactam compounds, which exhibit stability to serine β-lactamases and metallo-β-lactamases, broad antibacterial spectrum, and are suitable for intravenous administration, with excellent pharmacokinetic properties.
The crystalline form A of the compound demonstrates high stability, broad antibacterial activity against carbapenem-resistant bacteria, good solubility, and effective treatment of bacterial infections, with a low incidence of drug resistance and favorable pharmacokinetic properties.
Smart Images

Figure 2024541775000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to salt and crystalline forms of sulfonylurea ring-substituted compounds, and in particular, discloses a compound of formula (1), crystalline forms, methods for its preparation, pharma- ceutically acceptable salts, and uses thereof in the manufacture of medicaments for treating therapeutically relevant diseases. [Background technology]
[0002] β-lactam antibiotics are important antibiotics, and with the continuous emergence of drug resistance genes and antibiotic hydrolases such as extended-spectrum serine β-lactamases (ESBLs) and serine carbapenem enzymes (e.g. KPCs), the efficacy of existing antibiotics is increasingly unable to meet requirements. In particular, in the case of severe or multi-drug resistance mediated by metallo-β-lactamases (MBLs), traditional antibiotics such as penicillins, cephalosporins, and carbapenems are unable to combat infections caused by these resistant bacteria. As a countermeasure against this, monocyclic β-lactam antibiotics, represented by aztreonam, are a highly advantageous chemical series that are naturally stable against metallo-β-lactamases (MBLs).
[0003] The commercially available drug aztreonam has the disadvantages of low permeability, strong efflux, narrow antibacterial spectrum, and instability to extended-spectrum serine β-lactamases (ESBLs). In order to overcome these clinical problems, a strategy to increase permeability via siderophore has been introduced, such as Basilea (Patent Document 1) and Naeja Pharmaceuticals (Patent Document 2), which reported a corresponding series of molecules. Recently, Novartis (Patent Document 3) reported a study on overcoming drug resistance by modifying the substituents of the aztreonam molecule, and the general formula of the compound is shown as follows, where the Het group is a heteroaromatic ring or a heterocycle substituted with 1 to 2 heteroatoms.
[0004] [ka]
[0005] In light of the serious drug resistance situation, it is urgent to develop a new generation of monocyclic β-lactam antibiotics to solve the current drug resistance problem, and the sulfonylurea ring-substituted monocyclic β-lactam molecule of the present invention has the corresponding potential.
[0006] Patent Document 4 described sulfonylurea ring-substituted monocyclic β-lactam compounds, the structure of which is shown in formula (BI), which are mainly used for the treatment of diseases related to bacterial infections.
[0007] [ka] [Prior art documents] [Patent documents]
[0008] [Patent Document 1] WO 2007065288 [Patent Document 2] WO 2002022613 [Patent Document 3] WO 2015148379 [Patent Document 4] PCT / CN2020 / 130568 Summary of the Invention
[0009] The present invention provides a crystalline form A of compound of formula (1), whose X-ray powder diffraction pattern has characteristic diffraction peaks at 2θ angles of 15.05±0.20°, 19.11±0.20°, and 21.15±0.20°.
[0010] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form A has characteristic diffraction peaks at 2θ angles of 15.05±0.20°, 19.11±0.20°, 20.41±0.20°, 21.15±0.20°, 22.62±0.20°, 23.48±0.20°, 27.32±0.20°, and 29.25±0.20°.
[0011] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form A has characteristic diffraction peaks at 2θ angles of 9.10±0.20°, 11.29±0.20°, 12.76±0.20°, 15.05±0.20°, 16.39±0.20°, 19.11±0.20°, 20.41±0.20°, 21.15±0.20°, 22.62±0.20°, and 23.68±0.20°.
[0012] In some embodiments of the invention, the X-ray powder diffraction pattern of crystalline form A has characteristic diffraction peaks at 2θ angles of 6.90±0.20°, 9.10±0.20°, 11.29±0.20°, 11.83±0.20°, 12.76±0.20°, 13.73±0.20°, 14.57±0.20°, 15.05±0.20°, 16.10±0.20°, 16.39±0.20°, 17.81±0.20°, 18.25±0.20°, 19.11±0.20°, 20.41±0.20°, and 21.15±0.20°.
[0013] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form A has characteristic diffraction peaks at 2θ angles of 6.90±0.20°, 9.10±0.20°, 11.29±0.20°, 11.83±0.20°, 12.76±0.20°, 13.73±0.20°, 15.05±0.20°, 16.39±0.20°, 17.81±0.20°, 19.11±0.20°, 20.41±0.20°, 21.15±0.20°, 21.64±0.20°, 22.62±0.20°, and 23.48±0.20°.
[0014] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form A is 6.90±0.20°, 9.10±0.20°, 11.29±0.20°, 11.83±0.20°, 12.76±0.20°, 13.73±0.20°, 15.05±0.20°, 16.39±0.20°, 17.81±0.20°, 19.11±0.20°, 18.21±0.20°, 19.21±0.20°, 20.08±0.20°, 21.03±0.20°, 22.03±0.20°, 23.03±0.20°, 24.03±0.20°, 25.03±0.20°, 26.03±0.20°, 27.03±0.20°, 28.03±0.20°, 29.03±0.20°, 30.03±0.20°, 31.03±0.20°, 32.03±0.20°, 33.03±0.20°, 34.03±0.20°, 35.03±0.20°, 36.03±0.20°, 37.03±0.20°, 38.03±0.20°, 39.03±0.20°, 40.03±0.20°, 41.03±0.20°, 42.03±0.20°, 43.03±0.20°, 44.03±0.20°, 45.03±0.20 It has characteristic diffraction peaks at 2θ angles of 20.5±0.20°, 20.41±0.20°, 21.15±0.20°, 21.64±0.20°, 22.62±0.20°, 23.48±0.20°, 25.73±0.20°, 26.43±0.20°, 27.32±0.20°, 28.42±0.20°, and 29.25±0.20°.
[0015] In some embodiments of the present invention, the X-ray powder diffraction pattern of Form A is 15.05±0.20°, 19.11±0.20°, 21.15±0.20°, and / or 6.90±0.20°, and / or 9.10±0.20°, and / or 11.29±0.20°, and / or 11.83±0.20°, and / or 12.76±0.20°, and / or 13.73±0.20°, and / or 14.57±0.20°. 0.20°, and / or 16.10 ± 0.20°, and / or 16.39 ± 0.20°, and / or 17.81 ± 0.20°, and / or 18.25 ± 0.20°, and / or 20.41 ± 0.20°, and / or 20.79 ± 0.20°, and / or 21.64 ± 0.20°, and / or 22.62 ± 0.20°, and / or 23.48 ± 0.20°, and / or 23.68 ± 0.20°, and / or 24.00 ± 0.20°, and / or 24.81 ± 0.20°, and / or 25.73 ± 0.20°, and / or 26.43 ± 0.20°, and / or 26.66 ± 0.20°, and / or 27.32 ± 0.20°, and / or 27.64 ± 0.20°, and / or 28.42 ± 0.20°, and / or 29.25 ± 0.20°, and / or 29.92 ± 0.20°, and / or 30.36 ± 0.20°, and / or 30.73 ± 0.20°, and / or 31.51 ± 0.20°, and / or 31.83 ± 0.20°, and / or 32.05 ± and / or 32.51±0.20°, and / or 32.84±0.20°, and / or 33.13±0.20°, and / or 33.84±0.20°, and / or 34.35±0.20°, and / or 34.90±0.20°, and / or 35.50±0.20°, and / or 36.04±0.20°, and / or 36.47±0.20°, and / or 37.10±0.20°, and / or 37.57±0.20°, and / or 37.88±0.20°, and / or 38.80±0.20°.
[0016] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form A is 6.904°, 9.095°, 11.285°, 11.833°, 12.757°, 13.732°. , 14.573°, 15.050°, 26.655°, 27.323°, 27.636°, 28.420°, 29.248°, 29.922°, 30.358°, 30.733°, 31.507°, 31.830°, 32.049°, 33.049°, 33.049°, 33.049°, 33.049°, 333.049°, 34.34°, 35.500°, 36.037°, 36.467°, 37.098°, 37.573°, 37.875°, and 38.797° 2θ angles.
[0017] In some embodiments of the present invention, the XRPD pattern of Form A is essentially as shown in FIG.
[0018] In some embodiments of the present invention, analytical data of the X-ray powder diffraction pattern of crystalline form A is shown in Table 1.
[0019] [Table 1]
[0020] In some embodiments of the present invention, the thermogravimetric analysis curve of the A crystalline form reaches a weight loss of 6.657% at 140.000°C±3.000°C and a weight loss of 12.576% at 205.000°C±3.000°C.
[0021] In some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form A is essentially as shown in FIG.
[0022] In some embodiments of the present invention, the differential scanning calorimetry curve for crystalline form A has an endothermic peak at 100.28°C±3.00°C, an endothermic peak at 127.61°C±3.00°C, an exothermic peak at 200.70°C±3.00°C, and an endothermic peak at 266.36°C±3.00°C.
[0023] In some embodiments of the present invention, the differential scanning calorimetry curve of crystalline form A is essentially as shown in FIG.
[0024] The present invention further provides the use of the compound of formula (1) or a crystalline form A thereof in the manufacture of a medicament for treating a disease associated with a bacterial infection. Effect of the Invention
[0025] The crystalline form A of the compound of formula (1) of the present invention is easy to obtain, has good physical and chemical stability, and has high industrial applicability and economic value. The present invention discloses a new class of monocyclic β-lactam compounds substituted with a sulfonylurea ring, which are stable against serine β-lactamase and metallo-β-lactamase. The compounds have a broad antibacterial spectrum against gram-negative bacteria, and have excellent antibacterial activity, especially against various carbapenem-resistant Enterobacteriaceae superbacteria expressing β-lactamase. The compounds disclosed in the present invention have good water solubility, are suitable for intravenous administration, have excellent pharmacokinetic properties, are safer, have good efficacy, and are used for the treatment of diseases associated with bacterial infection.
[0026] Definitions and Explanations The present invention employs the following abbreviations: aq stands for water, BOC stands for tert-butoxycarbonyl, which is an amine protecting group, TEMPO stands for 2,2,6,6-tetramethylpiperidine nitroxide, TCCA stands for trichloroisocyanuric acid, HCl stands for hydrochloric acid, TFA stands for trifluoroacetic acid, DCM stands for dichloromethane, MeCN stands for acetonitrile, (n-Bu)4NHSO4 stands for tetrabutylammonium hydrogen sulfate, IPA stands for isopropanol, eq stands for equivalents, the same amount, and CBz stands for benzyloxycarbonyl, which is an amine protecting group. [Brief description of the drawings]
[0027] [Figure 1]FIG. 1 is an XRPD spectrum of a crystalline form of compound A of formula (1). [Diagram 2] FIG. 2 is a TGA spectrum of the crystalline form of compound A of formula (1). [Diagram 3] This is a DSC spectrum diagram of the crystalline form of compound A of formula (1). (A peak information: total heat (endotherm) amount -189.19 mJ standard heat (endotherm) amount -82.26 Jg^-1 initial melting temperature 74.62°C peak value 100.28°C final melting temperature 120.89°C left limit temperature 47.75°C right limit temperature 113.15°C; B peak information: total heat (endotherm) amount -113.80 mJ standard heat (endotherm) amount -49.48 Jg^-1 initial melting temperature 105.72°C peak value 127.61°C final melting temperature 136.22°C left limit temperature 113.15°C right limit temperature boundary temperature 136.62℃; C peak information: total heat (endotherm) amount 1374.45mJ standard heat (endotherm) amount 597.59Jg^-1 initial melting temperature 170.56℃ peak value 200.70℃ final melting temperature 215.91℃ left limit temperature 136.62℃ right limit temperature 228.98℃; D peak information: total heat (endotherm) amount -888.43mJ standard heat (endotherm) amount -386.27Jg^-1 initial melting temperature 229.07℃ peak value 266.36℃ final melting temperature 299.00℃ left limit temperature 228.98℃ right limit temperature 350.12℃). [Figure 4] This is a simulated XRPD spectrum of the single crystal of the compound of formula (1) (wavelengths 1.54056; 14.585, 10366; h,k,l=4,0,-1). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] The present invention will be described in detail below with reference to examples, but this does not mean any unfavorable limitations on the present invention. The compounds of the present invention include the specific embodiments listed below, embodiments formed by combination with other chemical synthesis methods, and equivalent substitution forms known to those skilled in the art, and preferred embodiments include, but are not limited to, the embodiments of the present invention. It is obvious to those skilled in the art that various modifications and modifications can be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention. Example 1:
[0029] [ka]
[0030] [ka]
[0031] Step 1: Preparation of Compound A-2 Compound A-1 (1.00 kg, 6.85 mol, 1 eq) was dissolved in methanol (4 L), and Boc anhydride (1.63 kg, 7.46 mol, 1.71 L, 1.09 eq) was slowly added dropwise at 20 ° C. Potassium carbonate (1.09 kg, 7.88 mol, 1.15 eq) was dissolved in water (2 L), slowly added dropwise to the reaction system, and stirred at 20-30 ° C for 1 hour. Ethyl acetate (8 L) was added to the reaction solution, and the organic phase was combined and concentrated under reduced pressure. Ethyl acetate (15 L) was added to the residue, washed once with water (10 L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound A-2. 1 H NMR (400 MHz, CDCl3) δ = 5.01 (br s, 1H), 3.93 (br s, 1H), 3.65-3.50 (m, 2H), 3.44 (br d, J = 14.0 Hz, 1H), 3.33-3.19 (m, 1H), 1.46 (d, J = 1.9 Hz, 9H).
[0032] Step 2: Preparation of compound A-3 Compound A-2 (1.15 kg, 5.48 mol, 1 eq) was dissolved in ethanol (1.5 L) and cooled to 0-5°C. Sodium hydroxide (338.50 g, 6.03 mol, 1.1 eq) was dissolved in ethanol (4 L) and then slowly dropped into the reaction system. After the dropwise addition was completed, the temperature was slowly raised to 25°C and stirred at 25°C for 1 hour. 1N HCl was added to the reaction solution to adjust the pH to 7 and concentrated under reduced pressure. Ethyl acetate (5 L x 2) was added to the residue to extract, and the combined organic phase was washed once with brine (1 L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dissolved in a mixed solvent (5 L) of petroleum ether and ethyl acetate = 3:1, and 100-200 mesh silica gel (1.50 kg) was added at 15 ° C., stirred for 0.5 hours, filtered, and the filter cake was washed three times with a mixed solvent (5 L) of petroleum ether / ethyl acetate = 1 / 3, and the combined filtrate was concentrated under reduced pressure to obtain compound A-3. 1 H NMR (400 MHz, CDCl3) δ = 4.76 (br s, 1H), 3.62-3.50 (m, 1H), 3.28-3.19 (m, 1H), 3.11 (br s, 1H), 2.80 (t, J = 4.3 Hz, 1H), 2.61 (dd, J = 2.6, 4.7 Hz, 1H), 1.46 (s, 9H).
[0033] Step 3: Preparation of intermediate A Compound A-3 was dissolved in ethanol (5 L), and aqueous ammonia (4.55 kg, 32.46 mol, 5 L, purity 25%, 5.62 eq) was added at 0-5°C, and the mixture was heated to 20°C and stirred for 16 hours. The reaction solution was distilled under reduced pressure, and solid sodium chloride was added to the residue and stirred at 25°C for 0.5 hours. Ethyl acetate (2 L) was added once for extraction, and the aqueous phase was extracted with ethyl acetate (500 mL), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was slurried in petroleum ether / tert-butyl methyl ether = 1 / 1 at 20°C for 1 hour, filtered, and the filter cake was dried in vacuum to obtain intermediate A. 1H NMR (400 MHz, CDCl3) δ = 5.46-5.08 (m, 1H), 3.79-3.54 (m, 1H), 3.32-3.19 (m, 1H), 3.13-2.99 (m, 1H), 2.79 (dd, J = 4.0, 12.7 Hz, 1H), 1.43 (s, 9H).
[0034] Preparation of Intermediate B
[0035] [ka]
[0036] Compound B-1 (84.00 g, 593.50 mmol, 1 eq) was dissolved in dichloromethane (590 mL) at 0-10°C, and a solution of benzyl alcohol (66.11 g, 661.30 mmol, 1.03 eq) in dichloromethane (590 mL) was slowly added dropwise at 0-10°C under a nitrogen atmosphere, and the reaction solution was reacted in an ice bath for 0.5 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was slurried in petroleum ether (600 mL) at 25°C for 15 minutes and filtered to obtain intermediate B. 1 H NMR (400 MHz, CDCl3) δ = 7.51 - 7.36 (m, 5H), 5.33 (s, 2H).
[0037] Preparation of Intermediate C
[0038] [ka]
[0039] Step 1: Preparation of compound C-2 At 20-30°C, 1,8-diazabicyclo[5.4.0]undecan-7-ene (536.8g, 3.53mol, 531.5mL, 1.2eq) was added to a solution of compound C-1 (300.0g, 2.94mol, 1eq) and brominated diphenylmethane (835.2g, 3.38mol, 1.15eq) in toluene (3.5L), and the temperature was then raised to 75-80°C and the reaction was carried out for 5 hours. Cool the reaction solution to room temperature, add water (1 L) and stir for 0.5 h, separate the organic phase, wash with water (1 L × 2), concentrate under reduced pressure to about 500 mL, and add n-heptane (2 L) and heat to 75-80 °C to obtain a clear solution, cool it to room temperature, stir in ice water for 1 h, filter, wash the filter cake with toluene / n-heptane (600 mL, 1 / 5) and n-heptane (300 mL), dry the solid with an oil pump to obtain compound C-2. 1 H NMR (400 MHz, CDCl3) δ = 7.40-7.29 (m, 11H), 6.95 (s, 1H), 1.46-1.39 (m, 2H), 1.27-1.19 (m, 2H).
[0040] Step 2: Preparation of compound C-3 Sodium tert-butoxide was added in portions to a solution of compound C-2 (150.0 g, 559.1 mmol, 1 eq) and diphenylphosphonamide (156.5 g, 670.9 mmol, 1.2 eq) in tetrahydrofuran (1.5 L) at 0-10 ° C., and the temperature was controlled in the range of 0-10 ° C. and the reaction was carried out for 2 hours at 0-10 ° C. under nitrogen protection. 5% sodium chloride (1 L) was added to the reaction solution and stirred for 0.5 hours, after which the organic phase was separated, the aqueous phase was extracted with ethyl acetate (500 mL × 2), the organic phase was combined and washed with 5% sodium chloride solution (1 L × 2), dried over anhydrous sodium sulfate, and filtered to obtain a 2.5 L tetrahydrofuran / ethyl acetate solution of compound C-3, which was used as it was in the next reaction.
[0041] Step 3: Preparation of intermediate C Compound C-4 (106.6 g, 391.3 mmol, 0.7 eq) was added to 2.5 L of tetrahydrofuran / ethyl acetate solution of compound C-3 (158.4 g, 559.1 mmol, 1 eq), and reacted for 18 hours at 20 to 30 ° C. The reaction solution was concentrated under reduced pressure to obtain a residue, and then ethyl acetate (400 mL) was added, heated to 65 to 70 ° C., stirred for 0.5 hours, and then n-heptane (1.6 L) was added, cooled to room temperature, stirred in an ice bath for 0.5 hours, filtered, and the filter cake was washed with ethyl acetate / n-heptane (400 mL, 1 / 3) and dried under reduced pressure with an oil pump to obtain a residue. The residue was added to acetonitrile (580 mL) and acetone (1.45 L), stirred at 55-60°C for 3 hours, concentrated under reduced pressure at 40°C to remove acetone, repeatedly added acetonitrile (400 mL), concentrated under reduced pressure twice, added acetonitrile (360 mL), heated to 60°C, added dropwise with water (580 mL), cooled to room temperature, stirred for 1 hour, filtered, washed the filter cake with acetonitrile / water (300 mL, 1 / 1) and ice acetonitrile (100 mL) in that order, and dried the solid under reduced pressure with an oil pump to obtain a residue. 1 H NMR (400 MHz, DMSO-d6) δ = 11.83 (br s, 1H), 7.49 (s, 1H), 7.45 (dd, J = 1.8, 7.6 Hz, 4H), 7.30 - 7.21 (m, 6H), 6.88 (s, 1H), 1.51 (br d, J = 3.0 Hz, 2H), 1.48 (s, 9H), 1.45 - 1.40 (m, 2H).
[0042] Preparation of Compound of Formula (1)
[0043] [ka]
[0044] [ka]
[0045] Step 1: Preparation of Compound 1-2 Compound 1-1 (1.5 kg, 11.35 mol, 1 eq) is dissolved in DCM (15 L), and TEMPO (4.46 g, 28.38 mmol, 0.0025 eq) and sodium acetate (1.40 kg, 17.03 mol, 1.5 eq) are added at once under nitrogen protection at a temperature of 10-20 ° C., and then TCCA (1.06 kg, 4.54 mol, 0.4 eq) is added in portions over 1 hour at 0-10 ° C. The reaction solution is heated to 10-20 ° C. and stirred for 1 hour. The reaction solution is then filtered, and the filtrate is a dichloromethane solution of compound 1-2, which is used directly in the next step of the reaction.
[0046] Step 2: Preparation of Compounds 1-3 To the dichloromethane solution of compound 1-2, 1 eq of aqueous sodium carbonate was added, followed by the addition of 2,4-dimethoxybenzylamine (1.52 kg, 9.10 mol, 1.37 L, 1 eq), and the mixture was stirred at 10-15° C. for 0.5 hours. The reaction was stopped, the liquids were separated, and the organic phase was washed with saturated saline (5.0 L), dried over anhydrous sodium sulfate, and filtered. The filtrate was a dichloromethane solution of compound 1-3, which was used directly in the next step of the reaction. Step 3: Preparation of Compounds 1-5
[0047] Compound 1-4 (2.47 kg, 11.82 mol, 1.3 eq) was dissolved in dichloromethane (12.8 L), cooled to -40 ° C, triethylamine (3.59 kg, 35.46 mol, 4.94 L, 3.9 eq) was added, and the mixture was stirred at -30 to -20 ° C for 30 minutes. The dichloromethane solution of compound 1-3 was slowly added at -20 to -30 ° C, and then the temperature was raised to -20 to 10 ° C and stirring was continued for 6 hours. The reaction was stopped, and the mixture was washed successively with 3M HCl (6 L), saturated aqueous sodium bicarbonate solution (6 L) and brine (6 L), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was suspended in methanol, suspended and stirred at -30 to -20 ° C for 2 hours, and filtered to obtain compound 1-5 (880.0 g, 18.5% total yield for three steps).
[0048] Step 4: Preparation of Compounds 1-6 Compound 1-5 (131.0 g, 278.42 mmol, 1 eq) was added to tetrahydrofuran (1.2 L) and water (300 mL) at 20-30 °C, and p-toluenesulfonic acid monohydrate (37.07 g, 194.89 mmol, 0.7 eq) was stirred at 65 °C for 4 h. The mixture was cooled to 20 °C, the pH was adjusted to 7 using saturated sodium bicarbonate solution, and the mixture was concentrated under reduced pressure at 40 °C to remove tetrahydrofuran. Water (1.2 L) was added to the remaining mixture, stirred at 20-30 °C for 1 h, and filtered. The filter cake was rinsed with water (600 mL) to obtain compound 1-6.
[0049] Step 5: Preparation of Compounds 1-7 Compound 1-6 (119.85 g, 278.43 mmol, 1 eq) was added to ethyl acetate (1.2 L) and water (400 mL) at 20-30 °C, sodium periodate (65.51 g, 306.27 mmol, 1.1 eq) was added, and the mixture was stirred at 50 °C for 2 h. The temperature was lowered to 20-25 °C, the organic and aqueous phases were separated, the aqueous phase was extracted with ethyl acetate (300 mL × 2), the organic phases were combined, washed with 5% sodium chloride solution (300 mL), and concentrated under reduced pressure to obtain the crude product. The product was stirred with ethyl acetate (350 mL) at 20-30 °C for 5 h, and filtered to obtain compound 1-7. 1 H NMR (400 MHz, CDCl3) δ = 9.35 (d, J = 3.3 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.42- .27 (m, 6H), 7.19 (d, J = 8.3 Hz, 1H), 6.57 (d, J = 2.1 Hz, 1H), 6.51 (dd, J = 2.3, 8.3 Hz, 1H), 5.01 (s, 2H), 4.97-4.90 (m, 1H), 4.47-4.24 (m, 2H), 4.08 (dd, J = 3.3, 5.8 Hz, 1H), 3.76 (s, 3H), 3.73 (s, 3H).
[0050] Step 6: Preparation of Compounds 1-8 Compound 1-7 (78.00 g, 195.80 mmol, 1 eq) and 4A molecular sieves (150.00 g) were added to anhydrous dichloromethane (780 mL) at 0 °C, a solution of intermediate A (55.87 g, 293.67 mmol, 1.5 eq) in dichloromethane (200 mL) was added dropwise, stirred under nitrogen for 1 h, filtered, and the filtrate was added dropwise to a solution of sodium triacetoxyborohydride (82.99 g, 391.56 mmol, 2 eq) in acetic acid (200 mL) and stirred at 15-25 °C for 16 h under nitrogen protection. After concentrating under reduced pressure at 35°C, the mixture was diluted with water (1 L), extracted with ethyl acetate (800 mL x 2), dried over anhydrous sodium sulfate, filtered, and petroleum ether (1.5 L) was added to the filtrate. After stirring at 15 to 25°C for 1 hour, the precipitated white solid was filtered to obtain compound 1-8. 1 H NMR(400 MHz, DMSO) δ = 9.57-8.96 (m, 1H), 8.88-8.41 (m, 1H), 8.17 (br d, J = 9.3 Hz, 1H), 7.44-7.28 (m, 5H), 7.19 (d, J = 8.3 Hz, 1H), 6.90 (br s, 1H), 6.58 (d, J = 2.3 Hz, 1H), 6.50 (dd, J = 2.3, 8.3 Hz, 1H), 5.61 (br s, 1H), 5.15-5.01 (m, 2H), 4.99 (dd, J = 5.1, 9.4 Hz, 1H), 4.45-4.20 (m, 2H), 3.98 (br s, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 3.15 (br s, 1H), 3.06 (br s, 1H), 2.99-2.90 (m, 2H), 2.84 (br d, J = 10.9 Hz, 1H), 2.64 (br t, J = 10.2 Hz, 1H), 1.38 (s, 9H).
[0051] Step 7: Preparation of Compounds 1-9 Compound 1-8 (70.00 g, 122.24 mmol, 1 eq) and triethylamine (49.48 g, 488.96 mmol, 68.06 mL, 4 eq) were added to anhydrous tetrahydrofuran (700 mL), and a solution of intermediate B (46.69 g, 187.03 mmol, 1.53 eq) in anhydrous tetrahydrofuran (300 mL) was added dropwise at 0 ° C. To the mixture, a solution of intermediate B (6.10 g, 24.45 mmol, 0.2 eq) in anhydrous tetrahydrofuran (50 mL) was added dropwise, and the mixture was stirred at 15-25 ° C for 1 h to obtain a tetrahydrofuran solution of compound 1-9, which was used directly in the next step reaction.
[0052] Step 8: Preparation of Compounds 1-11 Compound 1-9 (97.43 g, 123.98 mmol, 1 eq) in anhydrous tetrahydrofuran (1.08 L) was added with triethylamine (25.09 g, 247.96 mmol, 34.51 mL, 2 eq), and methanesulfonyl chloride (17.31 g, 151.11 mmol, 11.70 mL, 1.22 eq) was added dropwise at 0 to 10°C, stirred for 3 hours, and methanesulfonyl chloride (16.16 g, 14 Dropwise addition of 1.07mmol, 10.92mL, 1.14eq) to the mixture, stirring at 0-10°C for 1h, lowering the temperature to 15-20°C, pouring the mixture into ice water (1.5L), extracting with ethyl acetate (1L x 2), washing the combined organic phase with brine (1L), drying with anhydrous water, concentrating under reduced pressure, adding ethyl acetate (500mL), stirring the mixture at 15-25°C for 16h, filtering to give compound 1-11. LCMS(ESI) m / z: 768.4(M+1).
[0053] Step 9: Preparation of Compounds 1-12 Compound 1-11 (20.00 g, 26.05 mmol, 1 eq) was dissolved in acetonitrile (200 mL) and water (100 mL), and the temperature was raised to 65-70 °C in a 100 °C oil bath. Potassium persulfate (31.68 g, 117.21 mmol, 4.5 eq) and potassium dihydrogen phosphate (18.15 g, 104.19 mmol, 4 eq) were added in one portion, and the mixture was refluxed for 1.5 hours. The mixture was then cooled to room temperature, filtered, saturated sodium bicarbonate (200 mL) was added, and the mixture was extracted with ethyl acetate (200 mL × 2). The organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by silica gel flash column chromatography (petroleum ether / ethyl acetate = 3 / 1 to 1 / 3, 10% dichloromethane) to obtain compound 1-12. 1 H NMR (400 MHz, CDCl3) δ = 7.44-7.20 (m, 11H), 6.02-5.50 (m, 1H), 5.31-5.16 (m, 2H), 5.11-4.90 (m, 4H), 4.02-3.97 (m, 1H), 3.97-3.86 (m, 1H), 3.70-3.44 (m, 2H), 3.43-3.09 (m, 3H), 2.97-2.81 (m, 1H), 1.89-1.57 (m, 1H), 1.36 (s, 9H).
[0054] Step 10: Preparation of Compounds 1-13 Compound 1-12 (300.0 g) and 3.0 L of methanol were placed in a 5 L glass reaction flask, stirring was started, the temperature was raised to 40 ° C, and stirring was continued until the raw materials were dissolved. Under nitrogen protection, Pd / C (15.0 g, purity 10%) was added, and 564.8 g of hydrogenated triethyl silicon was started to be added dropwise, and stirring was continued while maintaining a nitrogen flow environment. Under nitrogen protection, Pd / C (15.0 g, purity 10%) was added, and hydrogenated triethylsilyl was continued to be added dropwise. After the dropwise addition was completed, nitrogen protection was maintained, heating was stopped, and stirring was continued for 20 minutes. The reaction solution was suction filtered with diatomaceous earth, the filter cake was washed twice with methanol (500 ml × 2), and the filtrate was concentrated at 45 ° C. 5.0 L of tert-butyl methyl ether was added to the residue, stirred at 15-30°C for 18 hours, suction filtered under nitrogen protection, the filter cake was rinsed with 1.0 L of tert-butyl methyl ether, suction filtered, and the filter cake was dried by rotary evaporation using an oil pump (temperature: 50°C, time: 2 hours) to obtain compound 1-13.
[0055] Step 11: Preparation of Compounds 1-14 Compound 1-13 (20.50 g, 58.67 mmol, 1 eq) and intermediate C (28.39 g, 52.80 mmol, 0.9 eq) were dissolved in N,N-dimethylformamide (200 mL), N,N-diisopropylethylamine (22.75 g, 176.01 mmol, 30.66 mL, 3 eq) and 1-hydroxybenzotriazole (10.31 g, 76.27 mmol, 1.3 eq) were added, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (14.62 g, 76.27 mmol, 1.3 eq) was added, and the reaction solution was reacted under nitrogen protection at 15 to 25 ° C for 16 hours. The reaction mixture was poured into 1.5 L of ice water, stirred for 10 minutes, and then filtered. The filter cake was washed with water (300 mL x 2), and the filtrate was extracted with ethyl acetate (500 mL x 2). The filter cake was dissolved in the organic phase, washed successively with dilute hydrochloric acid (0.5 N, 100 mL x 2), saturated sodium bicarbonate (100 mL x 2), and brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel flash column chromatography (petroleum ether / ethyl acetate = 2 / 1 to 1 / 2, 10% dichloromethane) to obtain compound 1-14.
[0056] Step 12: Preparation of Compounds 1-15 Compound 1-14 (10.00 g, 11.51 mmol, 1 equiv.) was dissolved in N,N-dimethylformamide (50 mL), and sulfur trioxide N,N-dimethylformamide complex (13.63 g, 46.03 mmol, 47% purity, 4 equiv.) was added at 0-5 °C, and the mixture was stirred at 0-5 °C for 3 h. The mixture was poured into a mixed solvent of water (80 mL) and ethyl acetate (150 mL), separated, and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The organic layer was washed with brine (150 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1 to 0 / 1 + 10% dichloromethane) to give compound 1-15. LCMS (ESI) m / z: 949.1 (M+1).
[0057] Step 13: Preparation of compound of formula (1) Compound I-15 (6.20 g, 6.53 mmol, 1 eq) and anisole (7.06 g, 65.33 mmol, 7.10 mL, 10 eq) were dissolved in dichloromethane (60 mL), phosphoric acid (50.40 g, 437.14 mmol, 85% purity, 66.91 eq) was added at 0-5 °C, and the mixture was stirred at 0-5 °C for 1.5 h. The lower phosphoric acid phase in the mixture was added dropwise to tetrahydrofuran (300 mL) at 0-5 °C, stirred at 0-5 °C for 1 h, filtered under nitrogen protection, and the filter cake was rinsed with tetrahydrofuran (100 mL × 2) to obtain the crude product of formula (1), which was detected as an amorphous powder by XRPD. The crude product was dissolved in water (4 mL), filtered, and the filtrate was added dropwise to tetrahydrofuran (80 mL), and the mixture was stirred at 25-30 °C for 4 h, filtered under nitrogen protection, and the filter cake was rinsed with tetrahydrofuran (50 mL × 2) and dried to obtain the compound of formula (1). The compound of formula (1) is a crystal form A detected by XRPD. The ICPMS detection results showed that the sodium ion content was 1.59%, the phosphate ion content was 19.4%, and the water content was 7.5% by Karl Fischer water measurement, and the compound of formula (1) was revealed to be a salt form containing sodium 0.5, phosphate 1.5, and 3 crystal waters A. LCMS (ESI) m / z: 583.1 (M+1). 1 H NMR(400 MHz, DMSO-d6 + D2O) δ = 6.80 (s, 1H), 5.23 (d, J = 5.7 Hz, 1H), 4.17 (q, J = 5.7 Hz, 1H), 3.84 - 3.76 (m, 2H), 3.67 (br t, J = 8.9 Hz, 1H), 3.42 (br dd, J = 5.1, 14.4 Hz, 1H), 3.16 (br dd, J = 6.2, 14.2 Hz, 1H), 3.04 (br dd, J = 5.4, 9.9 Hz, 1H), 2.98 - 2.89 (m, 1H), 2.88 - 2.79 (m, 1H), 1.29 (br d, J = 9.4 Hz, 4H).
[0058] Example 2: Crystalline form of compound A of formula (1) Method 1: The crude product of the compound of formula (1) (0.50 g, 685.33 μmol) is dissolved in water (0.5 mL), insoluble impurities are filtered off, and the mixture is added dropwise to tetrahydrofuran (10 mL) at 25-30°C, stirred at 25-30°C for 4 hours, and after 4 hours, the mixture is uniformly dispersed, filtered under nitrogen protection, and dried to obtain the compound of formula (1) crystal form A.
[0059] Method 2: Dissolve the compound of formula (1) (100 mg, 137.07 μmol) in water (0.1 mL), add tetrahydrofuran (2 mL) dropwise to the solution until a solid precipitates, stir for about 2 hours to initiate hardening, gradually disperse, and after 4 hours, disperse uniformly, filter under nitrogen protection, and dry to obtain the compound of formula (1) crystal form A.
[0060] Method 3: The compound of formula (1) (20.00 mg, 27.4 μmol) was added with mixed solvents of water and tetrahydrofuran, respectively, and then water / tetrahydrofuran (1 / 15=0.5 mL), (1 / 20=0.5 mL), (1 / 25=0.5 mL), stirred at 25-30°C, and the solid was uniformly dispersed for about 5 hours, filtered under nitrogen protection, and dried to obtain the compound of formula (1) crystal form A.
[0061] Method 4: Dissolve compound of formula (1) (500 mg, 685.33 μmol) in water (1.0 mL), add 85% phosphoric acid (67.16 mg, 685.33 mmol), add tetrahydrofuran (20.0 mL) dropwise to the solution, stir at 15-25 °C for 12 h, filter under nitrogen protection, and dry to obtain compound of formula (1) crystalline form A.
[0062] Method 5: Dissolve compound of formula (1) (500 mg, 685.33 μmol) in water (1.0 mL), add 85% phosphoric acid (67.16 mg, 685.33 mmol), add isopropanol (6.0 mL) dropwise to the solution, stir at 15.25° C. for 12 hours, filter under nitrogen protection, and dry to obtain compound of formula (1) crystalline form A. Example 3: Confirmation of the configuration of the compound of formula (1)
[0063] Take 16 mg of the crystal form sample of formula (1) A, dissolve it in 900 μL of methanol / ethanol / water (1:1:1) at room temperature, put the sample solution into a 4 mL semi-sealed sample bottle, and slowly evaporate it at room temperature. The next day, colorless needle-like crystals were obtained.
[0064] The detected crystals were colorless and needle-shaped (0.30 × 0.10 × 0.10 mm 3 ) and belongs to the monoclinic C2 space group. Unit cell parameters are a = 25.3958(7) Å, b = 8.0781(2) Å, c = 14.8880(2) Å, α = 90°, β = 90.224(2)°, γ = 90°, V = 3054.25(12 ) Å3, and Z = 2. Calculated density Dc = 1.728 g / cm3, number of electrons in the unit cell F(000) = 1648.0, and linear absorption coefficient of the unit cell (Cu Kα) = 3.918 mm -1 , diffraction experiment temperature T = 149.99(11)K.
[0065] The three-dimensional structural ellipsoid diagram of the needle-like crystals is shown in FIG. 5, the simulated XRPD is shown in FIG. 4, and the structural data and parameters are shown in Tables 2-7.
[0066] [Table 2]
[0067] [Table 3]
[0068] [Table 4]
[0069] [Table 5]
[0070] [Table 6]
[0071] 1 +X,1+Y,+Z; 2 1 / 2+X,1 / 2+Y,+Z; 3 1 / 2+X,-1 / 2+Y,+Z; 4 1-X,+Y,1-Z; 5 3 / 2-X,-1 / 2+Y,1-Z; 6 3 / 2-X,1 / 2+Y,1-Z; 7 1-X, 1+Y, 1-Z
[0072] [Table 7]
[0073] Example 4: Preparation of other salt forms of the compound of formula (1) (1) Preparation of trifluoroacetic acid (TFA):
[0074] [ka]
[0075] Intermediate 1-15 (300 mg, 308.95 μmol, 1 eq) and anisole (66.82 mg, 617.91 μmol, 67.16 μL, 2 eq) were dissolved in DCM (3 mL) and the mixture was added with TFA (704.54 mg, 6.18 mmol, 457.49 μL, 20 eq) at 0 °C. The mixture was then stirred at 0-5 °C for 1 h. The mixture was then added with HO (140.04 mg, 7.77 mmol, 140.04 μL, 25.15 eq) at 0 °C and stirred at 25 °C for 24 h. At 0-5 °C, the lower aqueous phase / TFA was added dropwise to a cooled MeCN solution (8 mL). The mixture was then stirred at 0-5 °C for 0.5 h. The product was filtered under vacuum nitrogen to give the crude product (110 mg, 168.67 μmol, 54.59% yield, 89.33% purity) as an off-white solid, which was dissolved in 5 mL of water, adjusted to pH = 7-8 with saturated sodium bicarbonate at 0 °C, and treated with (n-Bu)4NHSO4 to pH = 4-5. 18 250*50mm*10μm, mobile phase: acetonitrile / water (10mM NH4HCO3), acetonitrile percentage from 5% to 30%, 21min), then purified by preparative HPLC (column: Phenomenex Synergi Max-RP 250*50mm*10μm, mobile phase: acetonitrile / water (0.1% TFA), acetonitrile percentage from 0% to 25%, 21min) to obtain compound of formula (II), detected as amorphous powder by XRPD. LCMS (ESI) m / z: 583.1 (M+1). 1H NMR (400 MHz, D2O) δ = 6.80 (s, 1H), 5.23 (d, J = 5.7 Hz, 1H), 4.17 (q, J = 5.7 Hz, 1H), 3.84 - 3.76 (m, 2H), 3.67 (br t, J = 8.9 Hz, 1H), 3.42 (br dd, J = 5.1, 14.4 Hz, 1H), 3.16 (br dd, J = 6.2, 14.2 Hz, 1H), 3.04 (br dd, J = 5.4, 9.9 Hz, 1H), 2.98 - 2.89 (m, 1H), 2.88 - 2.79 (m, 1H), 1.29 (br d, J = 9.4 Hz, 4H).
[0076] (2) Production of sulfate (H2SO4): The reaction was complicated and no sulfate was obtained. (3) Preparation of hydrochloride (HCl) The starting material was completely consumed, but no product was produced. (4) Preparation of acetate (AcOH) The starting material was completely consumed, but no product was produced. (5) Production of p-toluenesulfonate (TsOH): The raw material was completely consumed, but no product was produced.
[0077] Conclusion: Some other salt forms of the compound of formula (1) cannot be obtained directly.
[0078] Example 5: Stability study of crystalline forms of Compound A of formula (1) in different solvents The crystal form of compound A of formula (1) (30.00 mg, 44.08 μmol, 1 eq) was suspended in ethanol (0.2 mL), isopropanol (0.2 mL), acetonitrile (0.2 mL), ethyl acetate (0.2 mL), tetrahydrofuran (0.2 mL), ethanol / water = 20 / 1 (0.2 mL), isopropyl alcohol / water = 20 / 1 (0.2 mL), and acetonitrile / water = 20 / 1 (0.2 mL) at 20-30 degrees for 2 days, filtered under nitrogen protection, and dried. The results are shown in Table 8.
[0079] [Table 8]
[0080] Conclusion: The crystalline form of compound A of formula (1) can exist stably in various solvents, and is easily obtained with good reproducibility.
[0081] Example 6: Search for other crystal forms of the compound of formula (1) Objective: To explore other crystal forms by changing crystallization conditions.
[0082] [Table 9]
[0083] Conclusion: When using the crystalline form A of compound of formula (1) in different aqueous systems, other crystalline forms cannot be obtained after first dissolving and then crystallizing.
[0084] Example 7: Study on the solid-state stability of the crystalline form of Compound A of formula (1) The crystalline form of compound A of formula (1) was spread into a thin layer, which was fully exposed to high temperature, normal temperature and high humidity, light, high temperature and high humidity conditions, and samples were taken at the designated time points to detect XRPD, appearance, content and related substances, and compared with the results of the 0-day sample.
[0085] [Table 10]
[0086] Conclusion: Crystalline form A of compound of formula (1) is stable under high temperature, high humidity and light irradiation conditions, and no significant changes in substance and content were observed under conditions of 60°C, 25°C / 75% RH and light irradiation.
[0087] Biological activity evaluation of the crystalline form of compound A of formula (1) Experimental Example 1: Detection of antibacterial effect of the crystalline form of compound A of formula (1) (MIC) The minimum inhibitory concentration (MIC) of each compound was measured using three strains of Klebsiella pneumoniae ATCC BAA-205 (TEM-1 / SHV-1 / SHV-12), ATCC BAA-1705 (KPC-2), and ATCC BAA-2470 (NDM-1), Enterobacter cloacae ATCC BAA-1143 (AmpC), and two strains of Escherichia coli ATCC BAA-2523 (OXA-48), and ATCC 25922, according to the requirements of the Institute of clinical and Laboratory standard (CLSI) by microfluidic dilution method. Add two-fold serial gradient dilutions of compounds (final concentration range 0.125 μg / mL to 128 μg / mL) in a round-bottom 96-orifice plate (Cat. No. 3788, Corning) and plate overnight on Mueller Hinton II Agar (MHA, Cat. No. 211438, BD BBL TM ) Select fresh bacterial monoclones on plates and suspend in sterile saline sodium chloride to a concentration of 1 × 10 8 CFU / mL and 5 × 10 in Mueller-Hinton II Broth (MHB, Cat. No. 212332, BD BBLTM) adjusted again with cations. 5 The solution was diluted to CFU / mL and 100 μL was added to a round-bottom 96-orifice plate containing the drug. The plate was inverted and incubated at 37°C for 20-24 hours, and the MIC value was read. The lowest drug concentration that inhibited bacterial growth was defined as the MIC. The results are shown in Table 8. Colony forming units (CFU, colony forming unit) refers to the total number of bacterial colonies per unit volume.
[0088] [Table 11]
[0089] Conclusion: The crystalline form of compound A of formula (1) has good inhibitory effects on various bacteria.
[0090] Experimental Example 2: Pharmacokinetic study of the crystalline form of Compound A of formula (1) in rats The rodent pharmacokinetic profile of the compound after intravenous administration was tested using a standard protocol. Specifically, the candidate compound was administered intravenously to 7-10 week old SD male rats in the experiment. The compound was dissolved in saline to make a clear solution. Plasma samples were collected and analyzed by LC-MS / MS method, and the pharmacokinetic parameters were calculated. The drug displacement parameters of the crystalline form of Compound A of Formula (1) are shown in Table 12.
[0091] [Table 12]
[0092] Conclusion: The exposure of the compound of the present invention increases linearly, and subsequent studies have shown that within the safe range, the benefits of the maximum dose of the drug can be exerted, better clinical efficacy can be achieved, and the drug's prospects are good.
[0093] Experimental Example 3: Spontaneous drug resistance mutation rate (FOR) of compound A of formula (1) against Escherichia coli ATCC 25922
[0094] Using Escherichia coli ATCC 25922, a total number of 2.60E+08 CFU colonies were selected for screening by microfluidic dilution according to the requirements of the Institute of Clinical and Laboratory Standards (CLSI), and the colonies were cultured at 2x, 4x, 8x, 16x, and 32x the MIC (Minimum Inhibitory Concentration) for 24 and 48 hours, respectively, to calculate the drug resistance frequency. See Table 13 for details.
[0095] [Table 13]
[0096] Conclusion: Compound (1) has a low incidence of drug resistance at twice the MIC, showing promise for clinical use. The crystalline form A of compound (1) provided by the present invention has stable properties, good solubility and good hygroscopicity, and has good medical prospects.
[0097] The crystalline form A of compound (1) provided by the present invention is easy to prepare, the reagents used are common and readily available on the market, the price is low, a stable single crystalline form can be obtained by various preparation methods, the operation is simple, the conditions are mild, the purity is high, and the yield is high.
[0098] Experimental Example 4: In vivo efficacy of the crystal form of compound of formula (1) in a thigh muscle infection model 78 CD-1 female mice were divided into 26 cages, with 3 mice in each cage, and the day of infection was counted as day 0. On the fourth day, 150 mg / kg of the immunosuppressant cyclophosphamide was intraperitoneally injected, and on the first day, 100 mg / kg of the immunosuppressant cyclophosphamide was intraperitoneally injected to induce immunodeficiency in mice.
[0099] On the first day, the strain Klebsiella pneumoniae ATCC-BAA 2470 (NDM+) was revived on an MHA plate. The revived colonies were collected and dissolved in sterile saline to prepare a bacterial solution with a concentration of 5.95E+07 CFU / mL for infecting the thigh muscles of mice. The start time of infection was recorded as 0 h, and 100 μL of the bacterial solution was injected into each thigh muscle at 0 h, i.e., the inoculum amount was 5.95E+06 CFU / mouse. Two hours after infection, drugs were administered according to the experimental protocol. The specific experimental plan is as follows (see Table 14):
[0100] (1) 2 hours after infection: At the end of 25 cages of mice, thigh muscle tissue was collected and placed in 10 mL of sterile saline, the tissue was homogenized with a homogenizer, and the homogenate was gradient diluted and spotted, repeated twice for each mouse.
[0101] (2) 2 hours after infection: For the treatment of formula (1) compound A, the 1st to 24th cages were subcutaneously injected with a volume of 10 mL per kg of mouse body weight, with the total daily dose of cages 1-4 being 1600 mg / kg, the total daily dose of cages 5-8 being 480 mg / kg, the total daily dose of cages 9-12 being 160 mg / kg, the total daily dose of cages 13-16 being 48 mg / kg, the total daily dose of cages 17-20 being 16 mg / kg, and the total daily dose of cages 21-24 being 4.8 mg / kg. Each dose group was administered in four different dose fractions, q3h, q6h, q12h, and q24h, respectively.
[0102] (3) 26h after infection: The end point of the test was 26 hours after infection. The thigh muscle tissues of mice from cages 1 to 26 were collected and placed in 10mL of sterile saline, the tissues were homogenized with a homogenizer, the homogenates were gradient diluted and spotted, and each mouse was repeated twice. The bacterial load in the mouse thigh muscle tissue was counted, and the experimental results are shown in Table 15.
[0103] [Table 14]
[0104] [Table 15]
[0105] Conclusion: The crystalline form of compound A of formula (1) of the present invention has significant bactericidal effect in vivo, with obvious dose-effect relationship, and the efficacy in vivo can be significantly improved by shortening the administration interval under the same daily dose.
Claims
1. Formula (1): [Formula 1] As shown in A pharmaceutical salt of a compound and its crystalline form.
2. The X-ray powder diffraction pattern has characteristic diffraction peaks at 2θ angles of 15.05±0.20°, 19.11±0.20°, and 21.15±0.20°, Formula (1): [chemical 2] As shown in A crystalline form A of a pharmaceutical salt of a compound,
3. The X-ray powder diffraction pattern has characteristic diffraction peaks at 2θ angles of 15.05±0.20°, 19.11±0.20°, 20.41±0.20°, 21.15±0.20°, 22.62±0.20°, 23.48±0.20°, 27.32±0.20°, and 29.25±0.20°. The crystalline form A of claim 2.
4. The X-ray powder diffraction pattern has characteristic diffraction peaks at 2θ angles of 9.10±0.20°, 11.29±0.20°, 12.76±0.20°, 15.05±0.20°, 16.39±0.20°, 19.11±0.20°, 20.41±0.20°, 21.15±0.20°, 22.62±0.20°, and 23.68±0.20°. The crystalline form A of claim 2.
5. The X-ray powder diffraction pattern has characteristic diffraction peaks at 2θ angles of 6.90±0.20°, 9.10±0.20°, 11.29±0.20°, 11.83±0.20°, 12.76±0.20°, 13.73±0.20°, 14.57±0.20°, 15.05±0.20°, 16.10±0.20°, 16.39±0.20°, 17.81±0.20°, 18.25±0.20°, 19.11±0.20°, 20.41±0.20°, and 21.15±0.20°. The crystalline form A of claim 2.
6. The X-ray powder diffraction pattern has characteristic diffraction peaks at 2θ angles of 6.90±0.20°, 9.10±0.20°, 11.29±0.20°, 11.83±0.20°, 12.76±0.20°, 13.73±0.20°, 15.05±0.20°, 16.39±0.20°, 17.81±0.20°, 19.11±0.20°, 20.41±0.20°, 21.15±0.20°, 21.64±0.20°, 22.62±0.20°, and 23.48±0.20°. The crystalline form A of claim 2.
7. The X-ray powder diffraction pattern was 6.90±0.20°, 9.10±0.20°, 11.29±0.20°, 11.83±0.20°, 12.76±0.20°, 13.73±0.20°, 15.05±0.20°, 16.39±0.20°, 17.81±0.20°, 19.11±0.20°, and 20. Characteristic diffraction peaks at 2θ angles of 41±0.20°, 21.15±0.20°, 21.64±0.20°, 22.62±0.20°, 23.48±0.20°, 25.73±0.20°, 26.43±0.20°, 27.32±0.20°, 28.42±0.20°, and 29.25±0.20° The crystalline form A of claim 2.
8. The X-ray powder diffraction pattern was: 6.904°, 9.095°, 11.285°, 11.833°, 12.757°, 13.732°, 14.573°, 15.050°, 16.100°, 16.389°, 17.807°, 18.251°, 19.113°, 20.413°, 20.790°, 21.147°, 21.641°, 22.615°, 23.484°, 23.676°, 24.002°, 24.812°, 25.728°, 26.433°, 26. Characteristic diffraction peaks at 2θ angles of 655°, 27.323°, 27.636°, 28.420°, 29.248°, 29.922°, 30.358°, 30.733°, 31.507°, 31.830°, 32.049°, 32.509°, 32.843°, 33.130°, 33.837°, 34.346°, 34.895°, 35.500°, 36.037°, 36.467°, 37.098°, 37.573°, 37.875°, and 38.797° The crystalline form A of claim 2.
9. The thermogravimetric analysis curve reaches a weight loss of 6.657% at 140.000°C ± 3.000°C and a weight loss of 12.576% at 205.000°C ± 3.000°C.
9. Crystalline form A according to any one of claims 2 to 8.
10. The thermogravimetric analysis curve is shown in FIG. 2 of the specification.
9. Crystalline form A according to any one of claims 2 to 8.
11. The differential scanning calorimetric curve has an endothermic peak at 100.28°C ± 3.00°C, an endothermic peak at 127.61°C ± 3.00°C, an exothermic peak at 200.70°C ± 3.00°C, and an exothermic peak at 266.36°C ± 3.00°C.
9. Crystalline form A according to any one of claims 2 to 8.
12. The differential scanning calorimetry curve is shown in FIG. 3 of the specification.
9. Crystalline form A according to any one of claims 2 to 8.
13. The XRPD pattern is as shown in FIG. 1 of the specification, and has the formula (1): [C3] As shown in A crystalline form A of a pharmaceutical salt of a compound,
14. The thermogravimetric analysis curve reaches a weight loss of 6.657% at 140.000°C ± 3.000°C and a weight loss of 12.576% at 205.000°C ± 3.000°C.
14. Crystalline form A of claim 13.
15. The thermogravimetric analysis curve is shown in FIG. 2 of the specification.
14. Crystalline form A of claim 13.
16. The differential scanning calorimetry curve has an endothermic peak at 100.28°C ± 3.00°C, an endothermic peak at 127.61°C ± 3.00°C, an exothermic peak at 200.70°C ± 3.00°C, and an endothermic peak at 266.36°C ± 3.00°C.
14. Crystalline form A of claim 13.
17. The differential scanning calorimetry curve is as shown in FIG. 3 of the specification.
14. Crystalline form A of claim 13.
18. 13. Use of the pharmaceutical salts and crystalline forms of claim 1 in the manufacture of a medicament for treating a disease associated with a bacterial infection.
19. 20. Use of crystalline form A according to any one of claims 2 to 17 in the manufacture of a medicament for treating a disease associated with a bacterial infection.
Citation Information
Patent Citations
Sulfonylurea ring substituted monocyclic β-lactam antibiotics
WO2021098840A1
3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
WO2002022613A1
Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
WO2007065288A2
Monobactam organic compounds for the treatment of bacterial infections
WO2015148379A1
